COGT250117C10000
- 0.03
- 0.000.00%
Cogent Biosciences Newsroom
Cogent Biosciences Is Maintained at Buy by HC Wainwright & Co.
Cogent Biosciences Analyst Ratings
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $23
Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $14
Buy Rating Maintained for Cogent Biosciences Amid Competitive Pressures and Promising Trial Results
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
Cogent Biosciences (COGT) Gets a Buy From J.P. Morgan
Cogent Biosciences Price Target Maintained With a $15.00/Share by Needham
Needham Downgrades Cogent Biosciences(COGT.US) to Hold Rating, Maintains Target Price $15
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Cogent Biosciences Analyst Ratings
Leerink Partners Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $16
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of Bezuclasinib
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15